Fig 1.
An overview of the paper acquisition. Finally, 53 articles were suitable for the analysis. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/joumal.pmed1000097. For more information, visit www.prisma-statement.org.
Fig 2.
QUADAS-2 quality assessment of the included studies.
There were no possible concerns of the references standard. A small amount of studies showed unclear bias regarding flow and timing, patient selection and index test.
Table 1.
Overview of the included tumor entities of the GLUT 1 analysis.
Fig 3.
Correlation between SUVmax and GLUT 1 expression.
Forrest plots of the correlations coefficients between SUVmax and GLUT 1 in all involved studies (n = 53) comprising 2291 patients. The pooled correlation coefficient was r = 0.46 (95% CI 0.40–0.52).
Fig 4.
Subgroup analyses for the correlation between SUVmax and GLUT 1 expression.
Forrest plots of the correlation coefficients between SUVmax and GLUT 1 in different primary tumors.
Fig 5.
Correlation between SUVmax and GLUT 3 expression.
Forrest plots of the correlations coefficients between SUVmax and GLUT 3 in 11 studies comprising 405 patients. The pooled correlation coefficient was r = 0.35 (95%CI 0.24–0.46).
Fig 6.
Subgroup analyses for the correlation between SUVmax and GLUT 3 expression.
Forrest plots of the correlation coefficients between SUVmax and GLUT 3 in HNSCC and NSCCL subgroups.
Table 2.
Overview of the included tumor entities of the GLUT 3 analysis.